IL17A and early-onset autosomal dominant Alzheimer disease: IL-17A is well recognized for its effects in neurological disorders, including multiple sclerosis (MS) [36,37,38], Alzheimer’s disease (AD) [39,40], Parkinson’s disease (PD) [41,42,43], and ischemic brain injury [44], and more recently with the development of anxiety and depression [24,29,45].